1. Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST CANCER INVASIVE DCIS DCIS PROSTATE CANCER Do I have aggressive disease? STAGE II/III COLON CANCER STAGE II/III COLON CANCER Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than 350,000 Patients

2. Oncotype DX Changed Treatment Decisions in Over One-Third of Breast Cancer Patients Leading to Less Toxicity and Healthcare Costs 2 * Based on meta-analysis of seven studies with 912 patients 1 grey 2 Key ChemotherapyNo Chemotherapy 3 halo 4 Women Diagnosed with Breast Cancer 1 text Treatment Plan Prior to Oncotype DX 2 text Treatment Plan After Oncotype DX 3 text Chemotherapy recommended for 62% of patients Bullet 1 Over a 37% Change in Treatment Decisions Bullet 2 Do I need chemotherapy? INVASIVE BREAST CANCER INVASIVE

3. Accurate Prediction of Prostate Cancer Risk is Needed at Time of Biopsy 3 Do I need surgery? PROSTATE CANCER

4. Oncotype DX Genomic Prostate Score Provides Significant Clinical Advantages and Actionable Information Optimized technology to analyze tiny needle biopsies Identified genes that predict disease aggressiveness and address tumor heterogeneity Established multiple biological pathways are highly significant Studied relevant patient populations Developed to answer critical treatment questions prior to intervention 4 "These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis.” —Peter Carroll, M.D., M.P.H. Chair, Department of Urology, University of California, San Francisco and Lead Investigator "These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis.” —Peter Carroll, M.D., M.P.H. Chair, Department of Urology, University of California, San Francisco and Lead Investigator Prostate Clinical Validation Study (American Urological Association Meeting May 2013)